Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Furst

Showing results (621-630 of 755) with videos related to

Pageof 76
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2020
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisChiara Bellocchi, Jun Ying, Ellen A Goldmuntz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2023
A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Christopher P Denton, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|August 14, 2009
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategyM Matucci-Cerinic, Y Allanore, L Czirják, et al.
Rheumatology (Oxford, England)|April 22, 2017
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort StudyLinda Kwakkenbos, Brett D Thombs, Dinesh Khanna, et al.
Seminars in Arthritis and Rheumatism|April 25, 2026
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT studyDorthe B Berthelsen, Tobias Haugegaard, Mohammed M Kamso, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Annals of the Rheumatic Diseases|October 9, 2003
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|July 2, 2020
Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working GroupSabrina Mai Nielsen, Helene Storgaard, Torkell Ellingsen, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.
Pageof 76

Showing results (621-630 of 755) with videos related to

Sort By:
Pageof 76
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2020
Large-Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung FibrosisChiara Bellocchi, Jun Ying, Ellen A Goldmuntz, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 14, 2023
A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Christopher P Denton, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|August 14, 2009
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategyM Matucci-Cerinic, Y Allanore, L Czirják, et al.
Rheumatology (Oxford, England)|April 22, 2017
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort StudyLinda Kwakkenbos, Brett D Thombs, Dinesh Khanna, et al.
Seminars in Arthritis and Rheumatism|April 25, 2026
Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT studyDorthe B Berthelsen, Tobias Haugegaard, Mohammed M Kamso, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Annals of the Rheumatic Diseases|October 9, 2003
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)D E Furst, F C Breedveld, J R Kalden, et al.
Annals of the Rheumatic Diseases|July 2, 2020
Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working GroupSabrina Mai Nielsen, Helene Storgaard, Torkell Ellingsen, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.
Pageof 76